AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06114550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low intensity resistance training
Description: For LIRT protocol, which performed same training exercises as HIRT. The repetitions in the LIRT protocol were assessed using the following equation: 80% of 1RM lifting load (kg) ×repetitions (HIRT)/40% of 1RM to volition fatigue, with 1-2 minutes of rest period between sets. Therefore, the LIRT protocol completed 4-5 sets of 24 repetitions at 40% of 1RM for a total of 60 minutes.
Study NCT05395052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent
Study NCT05395052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: For Cohort AA ONLY: To be combined with FT536 at the MTD or MAD
Study NCT05395052 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Monoclonal antibody
Study NCT05395052 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
Study NCT05395052 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
Study NCT05395052 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
Study NCT05395052 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Monoclonal antibody
Study NCT05395052 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Monoclonal antibody
Study NCT05395052 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Monoclonal antibody
Study NCT05395052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: For Cohorts BB-FF ONLY: To be combined with FT536 + mAb at the MTD or MAD
Study NCT06560671 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: novel type of health education
Description: animation video based health education
Study NCT06560671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: novel type of health education
Description: animation video based health education
Study NCT06173050 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PAP System A (with Amalfi) then PAP System B (with CLA11)
Description: PAP System A (with Amalfi) for 7 days followed by PAP System B (with CLA11) for 7 days
Study NCT06173050 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAP System B (with CLA11) then PAP System A (with Amalfi)
Description: PAP System B (with CLA11) for 7 days followed by PAP System A (with Amalfi) for 7 days
Study NCT05235568 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: VALVOSFT intervention
Description: Treatment of the calcific aorta valve by non-invasive ultrasound therapy
Study NCT05183282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tarsus Patch
Description: The Tarsus Patch is a flexible adhesive device that is applied to the closed upper eyelid and conforms to the curvature of the eyelid to help keep the eyelid in a closed position.
Study NCT06623227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsule contains substances that are safe, non-active, and commonly used in pharmaceuticals (microcrystalline cellulose) with an appropriate coloring dye and in the active arms, Vitamin E and C. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules
Study NCT06623227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E and C
Description: Capsule Vitamin E (Natural Vitamin E, d-alpha tocopherol) 150 IU or 200 IU containing also Vitamin C 100 mg or 200 mg b.id depending on age. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules
Study NCT06278233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: TDCS involves applying a weak electrical current across the head through electrodes placed on the scalp and modulating the resting membrane potential of neurons in the underlying cortex.
Study NCT06557369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reSEES
Description: The treatment consists of combining SMPL and PBM light therapies to exploit the full advantage of their action. The combination will result in an additive or synergetic effect.~* Treatment sessions are scheduled for three weeks after enrolment (Loading-Phase).~* Two visits per week are needed.~* At the first visit of every treatment week, two treatment sessions will follow each other; PBM is applied at least 15' after SMPL (treatment pairs).~* Only PBM will be administered during the second visit of every treatment week.~Patients will receive:~* 1x SMPL treatment at days 0, 7, and 14 (3 in total),~* 1x PBM treatment at days 0, 3, 7, 10, 14, and 17 (6 in total)~Nine treatments will be delivered within three weeks. The study will be concluded with three follow-up visits at 18, 24, and 54 weeks.
Study NCT05376202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800CW
Description: Patients will receive 75mg Cetuximab followed by 15mg Cetuximab-IRDye800CW two days prior to surgery
Study NCT04737122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-061
Description: Oral dose with approximately 240 mL water in the fasting condition, and food will be forbidden 1 h prior to administration and 2h after dose. QD for continuous 28 days, and 4 weeks as one treatment cycle.
Study NCT04737122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: For subjects in combination escalation levels, toripalimab will be administered 240mg, IV, every 3 weeks
Study NCT05673135 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anti-Hypertensive
Description: For control of the blood pressure
Study NCT05673135 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Ultrasound
Description: For assessment of gestational age and fetal weight
Study NCT05673135 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Doppler ultrasound
Description: Umbilical artery Doppler assessment
Study NCT05673135 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: complete blood count
Description: For assessment of platelet count
Study NCT05673135 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Body mass index
Description: for assessment of maternal weight during pregnancy
Study NCT06623695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: SGG performed the exercise program on a fixed ground surface. SGG exercise participants participated in a core exercise program for a total of 25-30 minutes, 2 days a week for 5 weeks.
Study NCT06623695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: USGG participants completed the exercise program on a bosuball. USGG exercise participants participated in a core exercise program for a total of 25-30 minutes, 2 days a week for 5 weeks.
Study NCT06622330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positioning
Description: Children in the experimental group were given 30 minutes of wrapping and 30 minutes of fetal position after aspiration.
Study NCT05173298 — intervention group
Intervention type: DRUG
Intervention: atezolizumab plus bevacizumab
Description: 1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks
Study NCT06596889 — intervention group
Intervention type: PROCEDURE
Intervention: Successful airway management
Description: * Types of equipment: Traditional oral airways, new airways, etc.~* Professional experience of the airway management practitioner (in years).~* If advanced, type of airway complication (bleeding, dental damage, mucosal damage, etc.), number of attempts~will be recorded separately for each patient.
Study NCT05323981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS627(210mg/7ml)
Description: Intravenous drip of 420mg HS627
Study NCT05608668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pro2 - 60% of participant's MIP
Description: Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 60% of their MIP.
Study NCT05608668 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pro2 - 15% of participant's MIP
Description: Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition
Study NCT05323981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS627(420mg/14ml)
Description: Intravenous drip of 420mg HS627
Study NCT05323981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perjeta
Description: Intravenous drip of 420mg PERJETA
Study NCT05605652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microosteoperforations
Description: Flapless micro-osteoperforations will be performed interproximally on the alveolar bone equidistant between upper right canine to upper left canine at every interdental alveolar bone except at the midline~alveolar bone to prevent trauma to the soft tissue frenum before placing the initial leveling archwire.
Study NCT05608239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra aesthetic
Description: The goal of the study is to evaluate the volumizing and bio-stimulatory effects of sculptra injections in the temples with total volume of the diluted product as 9 ml (8 ml of sterile water and 1 ml of Lidocaine).
Study NCT05443334 — intervention group
Intervention type: DRUG
Intervention: Semaglutide
Description: Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
Study NCT06305624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connections App
Description: mobile application, a place where participants can find community and support to help them manage their ALD, learn liver health self-care, coping skills, and alcohol abstinence strategies.
Study NCT05577715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-202
Description: Specified dose on specified days
Study NCT06247540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT06247540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04530474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Pill
Description: Ivermecin as a one-time dose
Study NCT04530474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive medication as a one time dose
Study NCT06247540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT06247540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT, CT
Study NCT06247540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06247540 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Receive IV
Study NCT06247540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06247540 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Receive IV
Study NCT06247540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Receive PO
Study NCT05497986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: HFNC with the maximum tolerated flow (up to 60 L/min). Titration of supplemental oxygen to a SpO2 between 88 - 92%.
Study NCT04969744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICE
Description: Intermittent Cooling Exposure using cooling garment for 1-2 hours
Study NCT05497986 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional low flow oxygenation
Description: Conventional oxygenation through nasal prongs or a facemask, with supplemental oxygen titrated to a SpO2 between 88 - 92%.
Study NCT05061355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heart valve surgery
Description: Heart valve surgery will be performed as soon as possible and preferably within 48 hours
Study NCT06562816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trypsin-Chymotrypsin
Description: 100000 IU
Study NCT06562816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium 550mg
Description: 550mg
Study NCT05280314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IO102-IO103
Description: IO102-IO103 is a combination of an indoleamine 2,3-dioxygenase 1 (IDO1) peptide (IO102) and a programmed death-ligand 1 (PD-L1) peptide (IO103), emulsified with an adjuvant (Montanide ISA 51 VG).
Study NCT05280314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab KEYTRUDA®
Description: Pembrolizumab KEYTRUDA® administered intravenously
Study NCT06171490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP2-4mg
Description: NP2-4 mg is a new product containing tobacco-derived nicotine.
Study NCT06171490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP2-6 mg
Description: NP2-6 mg is a new product containing tobacco-derived nicotine.
Study NCT06171490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Loz-4mg
Description: The Loz-4mg reference product is a commercially available 4mg nicotine lozenge.
Study NCT05187533 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Osteopathic protocol of Sphenopalatine Ganglion Stimulation
Description: Sphenopalatine Ganglion Stimulation to improve lacrimal and salivary gland secretion to improve ocular and oral dryness
Study NCT05655897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GeminiOne Transcatheter Valve Edge-to-Edge Repair System
Description: The transcatheter valve clamp system consists of a valve clamp, an adjustable bend mid-tube, and a manipulated inner tube. The adjustable bend introducer catheter consists of an adjustable bend outer tube and dilator. The valve clip is composed of nickel-titanium alloy, cobalt-chromium-nickel-molybdenum-iron alloy, and polyethylene terephthalate material and contains a closure clip, gripping tab, central mechanism, braid, and suture. The adjustable bend guiding catheter is used to provide access to the transcatheter valve clamping system and to reach the designated position. The adjustable curved mid-tube and manipulated inner tube are used to enable the delivery, gripping, and release process of the valve clips within the body.
Study NCT05250323 — intervention group
Intervention type: OTHER
Intervention: observational tests in face-to-face visit
Description: All necessary evaluations will be carried out for data collection. Also, that same day, the investigators will give the device to participants for the 7-day home assessment
Study NCT05150886 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: rox index
Description: After HFNC during reassessment, the ROX Index can help suggest which patients will fail HFNC and need to progress to intubation for further ventilatory support.
Study NCT06235905 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: NV-5138
Description: NV-5138 is a novel , orally bioavailable, activator of mTORC1
Study NCT06171490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gum-4mg
Description: The Gum-4mg reference product is a commercially available 4mg nicotine gum.
Study NCT05440760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Oculus Quest 2 Virtual Reality Headset
Description: The hardware includes the wireless headset with integrated headphones which will block the sight and sounds of the clinical setting as well as the hand controllers for the interactive VR experience, which will be delivered through any of three VR software options (subject may choose one or more from the following options):~* Titans of Space® PLUS developed by Drash VR, LLC (Murrieta, CA, USA)~* TRIPP® developed by TRIPP, Inc. (Los Angeles, CA, USA)~* Nature Treks VR published by Greener Games (Ironbridge, England, UK)
Study NCT05791903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing Care Based on Kolcaba's Comfort Theory
Description: Comfort-orientated care
Study NCT05888571 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prepectoral breast reconstruction
Description: Patients receive immediate prepectoral breast reconstruction
Study NCT05888571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prepectoral breast reconstruction
Description: Patients receive immediate prepectoral breast reconstruction
Study NCT05888571 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tiloop Mesh implantation
Description: Patients receive immediate prepectoral breast reconstruction with Tiloop Mesh
Study NCT05032976 — intervention group
Intervention type: BIOLOGICAL
Intervention: Tozinameran 12 Years of age and older
Description: BNT162b2 (purple cap) is administered with dilution, while BNT162b2 (grey cap) is administered without dilution. Both formulations are administered by intramuscular injection (IM) of 0.3 mL. According to the approved and authorized label, the recommended dose of BNT162b2 is a series of two doses (1 day 1 dose, 0.3mL each) 21 days apart and administered IM.
Study NCT05032976 — intervention group
Intervention type: BIOLOGICAL
Intervention: Tozinameran 5 to 11 Years of age
Description: BNT162b2 (orange cap) is administered with dilution by intramuscular injection (IM) of 0.2mL. According to the approved and authorized label, the recommended dose of BNT126b2 is a series of two dose (1day 1dose, 0.2mL) 21days apart and administered IM.~But, a third dose may be given at least 28 days after the second dose to individuals who are severely immunocompromised aged 5 to 11 years of age.
Study NCT05032976 — intervention group
Intervention type: BIOLOGICAL
Intervention: Tozinameran 6 months to 4 years of age
Description: BNT162b2 (maroon cap) is administered with dilution by intramuscular injection (IM) of 0.2mL. According to the approved and authorized label, it is recommended that the recommended dose of BNT162b2 is administered by intramuscular injection (IM) twice (once a day, each 0.2mL) at least of 21 days apart, and Dose 3 at least 8 weeks later.~Children who will turn from 4 years to 5 years of age between their doses in the vaccination course should receive their age-appropriate dose at the time of the vaccination and the interval between doses is determined by the child's age at the start of the vaccination course.~The interchangeability of BNT162b2 with COVID-19 vaccines from other manufacturers to complete the vaccination course has not been established.~BNT162b2 (6 months to 4 years of age) should be used only for infants and children 6 months to 4 years of age.
Study NCT05032976 — intervention group
Intervention type: BIOLOGICAL
Intervention: Riltozinameran 12 Years of age and older
Description: The bivalent COVID-19 Vaccine for omicron (BA. 1) (grey cap) is administered by intramuscular injection (IM) of 0.3mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 1) and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 1) is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19.
Study NCT05032976 — intervention group
Intervention type: BIOLOGICAL
Intervention: Famtozinameran 12 Years of age and older
Description: The bivalent COVID-19 Vaccine for omicron (BA. 4-5) (grey cap) is administered by intramuscular injection (IM) of 0.3mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 4-5) and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 4-5) is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19.